NEW YORK, June 12, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS), a leader in the emerging cellular therapy industry, is issuing this press release to clarify for shareholders that NeoStem is not engaged in a new financing. The registration statement filed today is merely a renewal of an outstanding registration statement covering the issuance of shares underlying warrants that were issued in 2011 and 2012 and remain outstanding. The underlying shares were previously registered, but the registration statement is expiring under SEC rules and needs to be refreshed.
No new securities are being offered by NeoStem.
About NeoStem
NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com